Literature DB >> 24639047

Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.

Nisha K Ramakrishnan1, Anniek K D Visser, Marianne Schepers, Gert Luurtsema, Csaba J Nyakas, Philip H Elsinga, Kiichi Ishiwata, Rudi A J O Dierckx, Aren van Waarde.   

Abstract

RATIONALE: Sigma-1 receptor agonists are under investigation as potential disease-modifying agents for several CNS disorders. Donepezil, an acetylcholinesterase inhibitor used for the symptomatic treatment of Alzheimer's disease, is also a high-affinity sigma-1 agonist.
OBJECTIVES: The objectives of the present study were to investigate if the sigma-1 agonist tracer (11)C-SA4503 and microPET can be used to determine sigma-1 receptor occupancy (RO) of donepezil in the rat brain; to establish RO of donepezil at doses commonly used in rodent behavioural studies; and to determine the effective plasma concentration of donepezil required for 50 % of max-min occupancy (EC50).
METHODS: Male Wistar rats were pre-treated with donepezil (0.1 to 10 mg/kg) for about 1 h before microPET scans using (11)C-SA4503. The total distribution volume (V T) of the tracer was determined by Logan graphical analysis using time activity curves from arterial plasma and regions of interest drawn around the entire brain and individual brain regions. RO by donepezil was calculated from a modified Lassen plot, and ED50 was estimated from the sigmoidal dose-response curves obtained when the RO was plotted against log donepezil dose.
RESULTS: A dose-dependent reduction was observed for V T in the whole brain as well as individual brain regions. RO increased dose-dependently and was 93 % at 10 mg/kg. ED50 was 1.29 mg/kg.
CONCLUSIONS: Donepezil, in the common dose range, was found to dose-dependently occupy a significant fraction of the sigma-1 receptor population. The data indicate that it is possible to determine sigma-1 RO by an agonist drug in rat brain, using (11)C-SA4503 and microPET.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24639047     DOI: 10.1007/s00213-014-3533-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.

Authors:  Montserrat Abadias; Marisol Escriche; Anna Vaqué; Mariano Sust; Gregorio Encina
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

3.  Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats.

Authors:  Ramakrishna Nirogi; Gopinadh Bhyrapuneni; Vishwottam Kandikere; Vijay Benade; Nageswararao Muddana; Ramanatha Saralaya; Shantaveer Irappanavar; Ranjithkumar Ponnamaneni; K Mukkanti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-02-03       Impact factor: 2.441

4.  Pharmacological interaction with the sigma1 (σ1)-receptor in the acute behavioral effects of antidepressants.

Authors:  Vanessa Villard; Johann Meunier; Nathalie Chevallier; Tangui Maurice
Journal:  J Pharmacol Sci       Date:  2011       Impact factor: 3.337

5.  Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.

Authors:  Valtteri Kaasinen; Kjell Någren; Tarja Järvenpää; Anne Roivainen; Meixiang Yu; Vesa Oikonen; Timo Kurki; Juha O Rinne
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

6.  Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.

Authors:  Catherine W Goh; Chiu Cheong Aw; Jasinda H Lee; Christopher P Chen; Edward R Browne
Journal:  Drug Metab Dispos       Date:  2010-12-08       Impact factor: 3.922

7.  Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease.

Authors:  W E Heydorn
Journal:  Expert Opin Investig Drugs       Date:  1997-10       Impact factor: 6.206

Review 8.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

9.  A template for spatial normalisation of MR images of the rat brain.

Authors:  Petra Schweinhardt; Peter Fransson; Lars Olson; Christian Spenger; Jesper L R Andersson
Journal:  J Neurosci Methods       Date:  2003-10-30       Impact factor: 2.390

10.  Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.

Authors:  N Narita; K Hashimoto; S Tomitaka; Y Minabe
Journal:  Eur J Pharmacol       Date:  1996-06-20       Impact factor: 4.432

View more
  12 in total

1.  Wildtype sigma-1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity.

Authors:  Yasuharu Shinoda; Yudai Haga; Koichiro Akagawa; Kohji Fukunaga
Journal:  J Biol Chem       Date:  2020-10-14       Impact factor: 5.157

2.  Altered sigma-1 receptor expression in two animal models of cognitive impairment.

Authors:  Nisha K Ramakrishnan; Krisztina Marosi; Csaba J Nyakas; Chantal Kwizera; Philip H Elsinga; Kiichi Ishiwata; Paul G M Luiten; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

3.  Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy.

Authors:  Nisha K Ramakrishnan; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

Review 4.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

5.  Cocaine occupancy of sigma1 receptors and dopamine transporters in mice.

Authors:  John R Lever; Emily A Fergason-Cantrell; Lisa D Watkinson; Terry L Carmack; Sarah A Lord; Rong Xu; Dennis K Miller; Susan Z Lever
Journal:  Synapse       Date:  2015-12-24       Impact factor: 2.562

6.  Wildtype σ1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity.

Authors:  Yasuharu Shinoda; Yudai Haga; Koichiro Akagawa; Kohji Fukunaga
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

Review 7.  Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives.

Authors:  Francesca Serena Abatematteo; Mauro Niso; Marialessandra Contino; Marcello Leopoldo; Carmen Abate
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

8.  Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.

Authors:  Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2015-07-11       Impact factor: 4.530

9.  Distribution of intravenously administered acetylcholinesterase inhibitor and acetylcholinesterase activity in the adrenal gland: 11C-donepezil PET study in the normal rat.

Authors:  Tadashi Watabe; Sadahiro Naka; Hayato Ikeda; Genki Horitsugi; Yasukazu Kanai; Kayako Isohashi; Mana Ishibashi; Hiroki Kato; Eku Shimosegawa; Hiroshi Watabe; Jun Hatazawa
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [(11)C]SA4503.

Authors:  Nisha K Ramakrishnan; Anniek K D Visser; Anna A Rybczynska; Csaba J Nyakas; Paul G M Luiten; Chantal Kwizera; Jurgen W A Sijbesma; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.